glucose lowering for cardiovascular prevention

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultCardiovascular deathcardiovascular events

diabetes type 2

aleglitazar
ALEPREVENT     aleglitazarplaceboLow risk of bias -
ALECARDIO, 2014      NCTaleglitazarplaceboLow risk of bias negative15%-4%
alogliptin
EXAMINE, 2013      NCTalogliptinplaceboLow risk of bias negative-15%-4%
canagliflozin
CANVAS, 2017            NCTcanagliflozinplaceboLow risk of bias conclusive -13%-14%
dapagliflozin
DECLARE TIMI 58, 2018        NCTdapagliflozinplaceboLow risk of bias -
empagliflozin
EMPA-REG OUTCOME, 2015      NCTempagliflozinplaceboLow risk of bias conclusive-38%-14%
exenatide
EXSCEL, 2017    NCTexenatideplaceboLow risk of bias conclusive-12%-9%
glargine
ORIGINE, 2012      NCTinsulin glarginecontrolnegative2%
linagliptin
CAROLINA, 2012      NCTlinagliptinglimepirideLow risk of bias suggesting-54%
liraglutide
LEADER, 2016      NCTliraglutideplaceboLow risk of bias conclusive-21%-12%
lixisenatide
ELIXA          NCTlixisenatideplaceboLow risk of bias negative2%
pioglitazone
PROACTIVE      NCTpioglitazoneplacebo -
IRIS, 2016      NCTpioglitazoneplacebo -
saxagliptin
SAVOR TIMI, 2013      NCTsaxagliptinplaceboLow risk of bias negative3%
semaglutide
SUSTAIN 6, 2016      NCTsemaglutideplaceboLow risk of bias conclusive -2%-26%
sitagliptin
TECOS, 2015          NCTsitagliptinplaceboLow risk of bias negative3%-1%